Selected articles
Articles for label Zezulová Michaela are displayed.. Show all articles
Do CDK4/6 inhibitors change existing treatment practice in metastatic HR+/HER2– breast cancer?
04/2018 MUDr. Michaela Zezulová, Ph.D.
Hormonal therapy allows patients with metastatic hormone-positive tumours to control disease while maintaining the best quality of life. The problem of its long-term administration is the emergence of resistance. CDK4/6 inhibitors represent a new therapeutic group of drugs when combined with hormonal agents provide significant benefit in delaying resistance and prolonging progression free survival with a favourable safety profile. The greatest benefit is apparently achieved with the use of CDK4/6 inhibitors already in the first line, but even in the 2nd line, therapy is very beneficial. Common inclusion of CDK4/6 inhibitors in therapeutic practice is expected soon, but we have to wait for results of clinical trials for the optimal therapeutic sequence.
ENTIRE ARTICLE
Hormonal therapy allows patients with metastatic hormone-positive tumours to control disease while maintaining the best quality of life. The problem of its long-term administration is the emergence of resistance. CDK4/6 inhibitors represent a new therapeutic group of drugs when combined with hormonal agents provide significant benefit in delaying resistance and prolonging progression free survival with a favourable safety profile. The greatest benefit is apparently achieved with the use of CDK4/6 inhibitors already in the first line, but even in the 2nd line, therapy is very beneficial. Common inclusion of CDK4/6 inhibitors in therapeutic practice is expected soon, but we have to wait for results of clinical trials for the optimal therapeutic sequence.